MOMarina A. Ovchinnikova

Marina A. Ovchinnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marina A. Ovchinnikova has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PERCUTANEOUS MITRAL VALVE REPAIR IN ACUTE POST-INFARCTION MITRAL REGURGITATION AS A BRIDGE TO ORTHOTOPIC HEART TRANSPLANTATION: A CLINICAL CASE

    by Alexey A. Baranov, Elena N. Pavlyukova, Marina A. Ovchinnikova, Aram G. Badoyan, Dmitrii A. Khelimskii, Aryuna Yu. Tsydenova, Mamurzhon A. Makhmudov, Aleksey G. Kuchumov, Aleksey G. Filippenko, Vladimir A. Boboshko, et al.

    Highlights We present a clinical case demonstrating the feasibility of transcatheter mitral valve repair using the MitraClip system as an effective bridging therapy to orthotopic heart transplantation in a high-surgical-risk patient with severe functional mitral regurgitation secondary to acute myocardial infarction.   Abstract While the impact of percutaneous mitral valve repair (MitraClip) on outcomes in chronic, severe, symptomatic mitral regurgitation has been extensively studied for many years, data on the use of this edge-to-edge percutaneous mitral valve repair in patients with severe, acute mitral regurgitation are scarce and limited to isolated reports or small registries. In some patients, the MitraClip procedure may serve as a bridge to surgical correction of mitral regurgitation, and in some cases, to orthotopic heart transplantation. In this paper, we describe a clinical case of the use of the MitraClip technology in acute post-infarction mitral regurgitation as a bridge to subsequent orthotopic heart transplantation.

  • Open Access

    Safety of intracoronary iopromide solution for experimental pharmaco-cold ex vivo preservation of donor heart

    by M.O. Zhulkov, D.A. Sirota, I.S. Zykov, A.K. Sabetov, H.A. Agaeva, A.G. Makaev, D.M. Osintsev, A.E. Kalendarev, A.P. Nadeev, V.E. Kliver, et al.

    Objective: To evaluate the effect of intracoronary iopromide (Ultravist®, Bayer, AG, Leverkusen, Germany) during pharmaco-cold ex vivo preservation of a donor heart on the restoration of heart pumping function and cardiomyocyte metabolism in the early post-transplant period.Methods: Black-and-white calves aged 3 months were used as an experimental model. In the control group, pharmaco-cold preservation of the donor heart was performed by injecting 2 liters of custodiol (Custodiol®, Dr. Franz Köhler Chemie GmbH, Bensheim, Germany) into the aortic root. The hearts were then stored in an appropriate solution at 0 to 1°C for 2 hours. In the experimental group (n = 6), a solution of iopromide and custodiol were injected into the aortic root at a ratio of 50:50 under a pressure of 70-80 mm Hg for 5 minutes after 120 minutes of preservation. Then the coronary bed was washed with 1 liter of custodiol at a pressure of 40 mm Hg and orthotopic heart transplantation was performed. In the post-transplant period, the parameters of central hemodynamics, myocardial oxygen consumption, and the levels of myocardial ischemia markers (troponin I, creatine phosphokinase-MB, lactate dehydrogenase) were assessed.Results: Twelve orthotopic heart transplantations were performed during the study. In 120 minutes after the restoration of spontaneous cardiac activity, the level of cardiac output was 5.11 [4.99; 5.41] L/min and 5.77 [4.97; 6.62] L/min (p = 0.0009) in the control and experimental groups, respectively. Changes in the concentration of lactate dehydrogenase, troponin I and lactate in the blood flowing from the coronary sinus were significantly higher in the early reperfusion period. However, no statistically significant difference was observed between the groups (p > 0.05). Myocardial oxygen consumption was significantly reduced at reperfusion. However, the initial values were restored by reperfusion minute 60 without any significant intergroup difference (p > 0.05).Conclusion: We established the safety of intracoronary iopromide administration for pharmaco-cold ex vivo preservation of the donor heart. Intracoronary administration of iopromide solution does not affect the restoration of the pumping function of the heart or metabolism in cardiomyocytes in the early post-transplant period. Received 6 May 2022. Revised 14 June 2022. Accepted 11 July 2022. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Contribution of the authorsConception and study design: M.O. Zhulkov, D.A. Sirota, I.S. ZykovData collection and analysis: M.O. Zhulkov, I.S. Zykov, A.K. Sabetov, H.A. Agaeva, A.G. Makaev, D.M. Osintsev, A.E. Kalendarev, A.P. Nadeev, V.E. Kliver, A.R. Tarkova, M.A. Ovchinnikova, N.A. Karmadonova, D.V. KhomushkuStatistical analysis: M.O. Zhulkov, A.G. MakaevDrafting the article: M.O. ZhulkovCritical revision of the article: M.O. Zhulkov, D.A. Sirota, I.S. Zykov, A.V. FomichevFinal approval of the version to be published: M.O. Zhulkov, D.A. Sirota, I.S. Zykov, A.K. Sabetov, H.A. Agaeva, A.G. Makaev, D.M. Osintsev, A.E. Kalendarev, A.P. Nadeev, V.E. Kliver, A.R. Tarkova, M.A. Ovchinnikova, A.V. Fomichev, N.A. Karmadonova, D.V. Khomushku


  • Open Access

    Meshalkin National Medical Research Center

    by A. V. Bogachev-Prokofiev, R. M. Sharifulin, D. A. Astapov, M. A. Ovcharov, M. A. Ovchinnikova, S. O. Lavinyukov, A. V. Sapegin, A. V. Afanasyev, S. I. Zheleznev, V. M. Nazarov, et al.

    We present three cases of successful transatrial transcatheter valve-in-valve implantation in patients with bioprosthetic mitral valve dysfunction. Patients with a high surgical risk, with severe heart failure due to bioprosthetic mitral valve dysfunction, were implanted with transcatheter prostheses using the transatrial approach.Transesophageal echocardiography and fluoroscopy-guided transcatheter mitral prosthetic valve positioning was performed. With a cardiac pacing at 180 bpm, a transcatheter valve was implanted. The transcatheter valves functioned properly after surgery. The patients were discharged in satisfactory condition.

  • Open Access

    Edge-to-edge mitral valve repair in the surgical treatment of hypertrophic cardiomyopathy

    by С. А. Будагаев, А. В. Афанасьев, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, А. Н. Пивкин, Д. А. Астапов, И. И. Демин

    Septal myectomy is the method of choice for treating symptomatic left ventricular outlet obstruction in patients with hypertrophic cardiomyopathy who are resistant to drug therapy. An important role in persistence, residual obstruction, mitral valve abnormalities and anterior systolic mitral valve movement is systolic anterior motion. Several authors have reported the use of edge-to-edge mitral valve repair in addition to septal myectomy in patients with mild septal hypertrophy. We performed a literature review on the surgical treatment of obstructive hypertrophic cardiomyopathy—mitral valve repair using the edge-to-edge technique with septal myectomy. Four retrospective studies and three clinical cases were analysed. The data of patients who underwent mitral valve repair surgery using the edge-to-edge technique with septal myectomy and had satisfactory long-term clinical and hemodynamic results were studied. This treatment technique should be considered in cases of unexpressed hypertrophy when isolated limited myectomy is insufficient to eliminate the left ventricular outlet or when there is a hemodynamically significant mitral insufficiency caused by anterior systolic movement of the mitral valve that increases the need for intervention on interventricular hypertrophy of the associated disease. Septal defect, plastic mitral valve, surgically significant residual mitral regurgitation and high residual left ventricular outflow gradients in long-term follow-up are feasible, safe and effective for anterior systolic mitral valve movement. Received 28 September 2020. Revised 23 March 2021. Accepted 25 March 2021. Funding: The study did not have sponsorship. Conflict of interest: Authors declare no conflict of interest. Author contributionsConception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-ProkophievData collection and analysis: S.A. Budagaev, M.A. Ovchinnikova, A.N. Pivkin, I.I. DeminDrafting the article: S.A. Budagaev, A.V. AfanasyevCritical revision of the article: A.V. Bogachev-Prokophiev, D.A. AstapovFinal approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, M.A. Ovchinnikova, A.N. Pivkin, D.A. Astapov, I.I. Demin


  • Open Access

    First experience of transcatheter implantation of a Russian-made MedLab-CT prosthesis in a patient with dysfunction of biological mitral valve prosthesis

    by A. V. Bogachev-Prokofiev, R. M. Sharifulin, M. A. Ovcharov, A. N. Pivkin, O. V. Krestyaninov, T. V. Antropova, M. A. Ovchinnikova, D. A. Astapov, A. V. Sapegin, A. V. Afanasyev, et al.

    We present a case report of successful transcatheter implantation of a Russian-made cardiac valve prosthesis in a patient with dysfunction of biological mitral valve prosthesis (valve-in-valve). A patient aged 78 years with a high surgical risk and severe heart failure due to mitral valve bioprosthesis dysfunction is described. Fluoroscopyand transesophageal echocardiography-guided transapical implantation of a MedLab-CT prosthesis (23 mm) was made. When a heart rate of 180 beats per minute, a stent prosthesis was implanted. Transcatheter implant valve functioned properly after surgery. The patient was discharged in satisfactory condition.